Radiotherapy for ductal carcinoma of the prostate: an analysis based on the Japanese radiation oncology study group survey.
Jpn J Clin Oncol
; 53(2): 146-152, 2023 Jan 28.
Article
en En
| MEDLINE
| ID: mdl-36478251
ABSTRACT
BACKGROUND:
The clinical characteristics of prostate ductal carcinoma is still unclear, and treatment strategy has not yet been established due to its rarity. Therefore, we conducted a multicenter survey of radiation therapy for prostate ductal carcinoma in Japan.METHOD:
Data of patients with ductal carcinoma of the prostate treated with radiation therapy between 1996 and 2018 were extracted from the database of each facility.RESULTS:
Fifty-two treatment records of 41 patients were collected from nine institutions. The treatment purpose and situations were varied curative intent to palliation. Twenty-eight patients received curative treatments. The median follow-up period of these patients was 68 months. Androgen deprivation therapy was combined with radiation therapy in 26 cases (93%). X-ray and particle irradiation was used. Radiation dose range was 63-78 Gy; 5-year overall survival, progression-free survival and biochemical relapse-free survival were 87.0, 79.3 and 79.3%, respectively. One patient experienced Grade 3 radiation proctitis and one experienced Grade 3 radiation cystitis. There were no Grade 4 or worse adverse events.CONCLUSION:
Most patient received similar treatment with adenocarcinoma of prostate, and the clinical results were compatible. For more reliable evidence, further studies are required.Palabras clave
Texto completo:
1
Colección:
01-internacional
Banco de datos:
MEDLINE
Asunto principal:
Neoplasias de la Próstata
/
Oncología por Radiación
/
Carcinoma Ductal
Tipo de estudio:
Clinical_trials
Límite:
Humans
/
Male
Idioma:
En
Revista:
Jpn J Clin Oncol
Año:
2023
Tipo del documento:
Article
País de afiliación:
Japón